CDC Home
Safer, Healthier People
CDC HomeCDC SearchHealth Topics A-Z
 
  WONDER Home FAQs Help Contact Us Search  
 

Warning:

This document is being maintained for historical purposes, but is now out of date. To view current guidelines please visit:


1998 Guidelines for Treatment of Sexually Transmitted Disease

Date: 01/23/98

Source: 47(RR-1);1-118

SUGGESTED CITATION: Centers for Disease Control and Prevention. 1998 Guidelines for Treatment of Sexually Transmitted Diseases. MMWR 1998;47(No. RR-1): {inclusive page numbers}.

The material in this report was prepared for publication by: National Center for HIV, STD and TB Prevention, Division of Sexually Transmitted Diseases Prevention

Abbreviations Used in This Publication

ACIP        Advisory Committee on Immunization Practices 
ACOG        American College of Obstetricians and Gynecologists 
ACS         American Cancer Society 
AIDS        Acquired immunodeficiency syndrome 
anti-HBc    Antibody to hepatitis B core antigen 
ASCUS       Atypical squamous cells of undetermined significance 
BCA         Bichloroacetic acid 
BV          Bacterial vaginosis 
CBC         Complete blood count 
CI          Confidence interval 
CIN         Cervical intraepithelial neoplasia 
CMV         Cytomegalovirus 
CSF         Cerebrospinal fluid 
d4t         Stavudine 
ddC         Dideoxycytodine 
ddI         Didanosine 
DGI         Disseminated gonococcal infection 
DNA         Deoxyribonucleic acid 
EIA         Enzyme immunoassay 
FDA         Food and Drug Administration 
FTA-ABS     Fluorescent treponemal antibody absorbed 
GISP        Gonococcal Isolate Surveillance Project 
HAV         Hepatitis A virus 
HBIG        Hepatitis B immune globulin 
HbsAg       Hepatitis B surface antigen 
HbeAg       Hepatitis B e Antigen 
HBV         Hepatitis B virus 
HIV         Human immunodeficiency virus 
HPV         Human papillomavirus 
HSV         Herpes simplex virus 
IFA         Immunofluorescence assay 
IG          Immune globulin 
IM          Intramuscularly 
IV          Intravenous or intravenously 
KOH         Potassium hydroxide 
LGV         Lymphogranuloma venereum 
MAC         Mycobacterium avium complex 
MIC         Minimum inhibitory concentration 
MPC         Mucopurulent cervicitis 
MHA-TP      Microhemagglutination assay for antibody to Treponema pallidum 
NGU         Nongonococcal urethritis 
OTC         Over-the-counter 
Pap         Papanicolaou 
PCP         Pneumocystis carinii pneumonia 
PCR         Polymerase chain reaction 
PID         Pelvic inflammatory disease 
PPD         Purified protein derivative 
PPV         Positive predictive value 
QRNG        Quinolone-resistant Neisseria gonorrhoeae 
RNA         Ribonucleic acid 
RPR         Rapid plasma reagin 
RVVC        Recurrent vulvovaginal candidiasis 
SAQ         Saquinavir 
SIL         Squamous intraepithelial lesions 
STD         Sexually transmitted disease 
TB          Tuberculosis 
TCA         Trichloroacetic acid 
TE          Toxoplasmic encephalitis 
TST         Tuberculin skin test 
VDRL        Venereal Disease Research Laboratory 
VVC         Vulvovaginal candidiasis 
WB          Western blot 
WBC         White blood cell 
ZDV         Zidovudine 
3TC         Lamivudine 



This page last reviewed: Thursday, September 04, 2014
This information is provided as technical reference material. Please contact us at cwus@cdc.gov to request a simple text version of this document.
  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
 Safer, Healthier People
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A.
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348
24 Hours/Every Day - Contact CDC-INFO
 USA.gov HomeDepartment of Health and Human Services Department of Health
and Human Services